BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Lantheus Medical Imaging 

331 Treble Cove Road
Building 600-2
North Billerica  Massachusetts  01862  U.S.A.
Phone: 800-299-3431 Fax: 978-436-7501


SEARCH JOBS



Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents and products that assist clinicians in the diagnosis of cardiovascular diseases such as coronary artery disease, congestive heart failure and stroke, peripheral vascular disease and other diseases. Clinicians use Lantheus’ imaging agents in conjunction with nuclear imaging, echocardiography and magnetic resonance imaging, or MRI.

Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection).

Lantheus Medical Imaging is committed to the field of nuclear medicine and to developing the next generation of diagnostic products to advance patient care. The company’s clinical development efforts include promising programs to develop novel Positron Emission Tomography (PET) imaging tracers, including flurpiridaz F 18, an F-18 labeled myocardial perfusion imaging agent which Lantheus recently initiated Phase 3 clinical trials, as well as LMI1195, a unique cardiac neuronal imaging agent which has completed Phase 1 clinical trials to evaluate safety and dosimetry. Lantheus has additional early stage programs in the areas of imaging vulnerable plaque and other disease states.

For more than half a century, Lantheus Medical Imaging has helped physicians enhance patient care with its pioneering product portfolio that illuminates the heart and other organs. Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont, and then Bristol-Myers Squibb (BMS) Medical Imaging. In 2008, BMS Medical Imaging was acquired by Avista Capital Partners and formally re-launched as Lantheus Medical Imaging, operating again as an independent company. Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia.

For more information, visit www.lantheus.com.




 Key Statistics


Email: bi.webadmin@lantheus.com
Ownership:

Web Site: Lantheus Medical Imaging
Employees:
Symbol: 
 









 Company News
Lantheus Medical Imaging Eyes IPO Worth Up To $125 Million 6/26/2014 7:02:19 AM
Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time 11/7/2013 7:58:26 AM
Lantheus Medical Imaging Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease 10/30/2013 7:25:45 AM
Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013 9/10/2013 6:45:21 AM
Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time 8/2/2013 7:02:38 AM
Lantheus Medical Imaging to Present at Wells Fargo Securities 2013 Healthcare Conference 6/12/2013 7:33:44 AM
Lantheus Medical Imaging to Present at Jefferies and Co. 2013 Global Healthcare Conference 5/29/2013 8:19:20 AM
Lantheus Medical Imaging to Host First Quarter 2013 Conference Call on May 14, 2013 at 4:00 P.M. Eastern Time 5/8/2013 7:43:30 AM
Lantheus Medical Imaging to Proceed With Flurpiridaz F 18 Phase 3 Clinical Program Based on Interim Analysis of Data From First Phase 3 Study 5/1/2013 11:21:18 AM
Lantheus Medical Imaging Focuses on Growth, Takes Steps to Reduce Expenses 3/22/2013 9:30:34 AM
12345678910...